drugset / Trial / NCT04635527

A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma

NCT04635527

Phase 1 Terminated 10 enrolled Innovent Biologics (Suzhou) Co. Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this phase Ib study is to assess the safety, tolerability and effectiveness of IBI318 in combination with conventional TACE (cTACE) in patients with potentially resected hepatocellular carcinoma.

Timeline

Start
2020-12-24
Primary completion
2021-08-27
Completion
2023-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI318 Unknown Intravenous